{"database": "lobbying", "table": "lobbying_activities", "rows": [[2682555, "a3df2660-d18e-4b67-86cf-7312571df5c8", "Q3", "MARSHALL & POPP, LLC", 401105121, "AMGEN USA INC.", 2021, "third_quarter", "PHA", "Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act; Budget reconciliation recommendations reported by House committees pursuant to S.Con.Res. 14.\n\nIssues related to supply chains, 340B, and the COVID-19 pandemic.", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-10-16T08:51:29.393000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2682555"], "units": {}, "query_ms": 0.9800558909773827, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}